Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'
February 27, 2024 12:06 PM ESTStifel analyst Samimy Annabel raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $80.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "Ahead of schedule, VKTX released the Ph.2 VENTURE data for injectable-VK2735, which again demonstrated a highly competitive profile relative to... More
Viking Therapeutics (VKTX) stock surges after phase 2 Venture trial meets primary and secondary endpoints
February 27, 2024 8:40 AM ESTViking Therapeutics (NASDAQ: VKTX) shares surged more than 80% premarket Monday after the company announced positive top-line results from its Phase 2 clinical trial of VK2735.
VK2735 is a medicine that may help treat obesity and other metabolic disorders. It works by targeting to... More
Viking Therapeutic's (VKTX) Obesity Data Seen as 'Impressive'
February 27, 2024 7:55 AM ESTTruist Securities analyst Joon Lee commented on Viking Therapeutic (NASDAQ: VKTX) following the release of positive top-line results from Phase 2 VENTURE trial of its dual GLP-1/GIP receptor agonist VK2735 in patients with obesity. The study achieved its primary and all secondary endpoints, demonstrating... More
